Arcellx Inc - Asset Resilience Ratio
Arcellx Inc (ACLX) has an Asset Resilience Ratio of 61.27% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Arcellx Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Arcellx Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Arcellx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACLX stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $370.07 Million | 61.27% |
| Total Liquid Assets | $370.07 Million | 61.27% |
Asset Resilience Insights
- Very High Liquidity: Arcellx Inc maintains exceptional liquid asset reserves at 61.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arcellx Inc Industry Peers by Asset Resilience Ratio
Compare Arcellx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Arcellx Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Arcellx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 61.27% | $370.07 Million | $603.99 Million | -6.45pp |
| 2024-12-31 | 67.72% | $481.70 Million | $711.33 Million | +30.46pp |
| 2023-12-31 | 37.26% | $307.43 Million | $825.13 Million | -23.50pp |
| 2022-12-31 | 60.75% | $190.66 Million | $313.82 Million | +3.46pp |
| 2021-12-31 | 57.29% | $73.78 Million | $128.78 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $57.69 Million | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more